The heartbeat of cardiovascular medicine and telemedicine
Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment
Message: CardioComm Solutions Provides Financing Update
Toronto, Ontario--(December 27, 2018) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, confirms the renewal of $600,000 in loans that would have matured December 31, 2018.
The maturing loans were made to the Company in December 2016 as described in the Company's press release dated December 21, 2016. The four lenders that participated in the 2016 financing have renewed their positions for the same aggregate amount of $600,000 until March 31, 2019. Three of the four lenders have also confirmed to the Company that effective April 1, 2019 they will extend at least $325,000 to the Company for another eighteen months, or until December 31, 2020, at the Company's discretion.
The Company also announces that it has issued 226,000 common shares to AGORA Internet Relations Corp. following approval from the TSXV. Shares were provided at a price of $0.05 per share for online marketing and awareness program services valued at $10,000 plus 13% HST. The Company previously announced the AGORA relationship in press releases dated November 8, 2018 and December 13, 2018.
To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
copyright (c) newsfile corp. 2018
Please login to post a reply